Our team

Caroline Goddeeris holds a PhD in Pharmaceutical Sciences followed by an MBA and master in corporate finance, both from Vlerick Business School. She started her career at UCB taking on various roles in strategy (portfolio management, business development, new product planning) and operations (marketing and sales). Prior to joining Fund+, Caroline was a principal at Gimv with board responsibilities at Complix and Multiplicom (sold to Agilent). Caroline currently serves on the board of Confo Therapeutics and  is responsible for the follow up of our Tubulis investment.

Bart De Leeuw joined Fund+ in 2023 as Partner & CFO. Prior to Fund+, he served as CFO and Risk Officer at Fortino Capital Partners and as Group Controller and Investment Manager at Ackermans & van Haaren. Earlier in his career, he spent over a decade at Ernst & Young, where he led the Technical Desk and was part of the EY global IFRS expert group in London.
Bart holds a Master’s degree in Commercial Sciences and a Master’s degree in Business Information Systems from University of Brussels.
He serves on the boards of Coave Therapeutics, EPICS Therapeutics, EyeD Pharmaceuticals, Minoryx Therapeutics and Novadip Biosciences.

Halina Novak, PhD, is an Associate Partner at Fund+. Halina brings extensive experience in technology innovation, investment and alliance management. Formerly, Halina held several leadership positions at VIB, the Flemish Institute for Biotechnology and worked at the intersection between industry, pharma and academia, leading large multi-stakeholder collaborations. Notably, she headed the Tech Watch Program and established the Technology Innovation Lab, where unique strategies were developed to identify, invest and evaluate breakthrough life science technologies in collaboration with start-ups and pharma. Many of these early-stage investments in disruptive tools have since revolutionised the Life Sciences. Halina started her career at Unilever on a fellowship that developed novel applications of industrial enzymes after having graduated from the University of Exeter with a PhD and BSc in Biological Sciences and Biological and Medicinal Chemistry, respectively. Halina previously represented Fund+ as a board member of Cardior Pharmaceuticals which was acquired by Novo Nordisk and is currently representing Fund+ as a Board member of Egle Therapeutics, Astrivax Therapeutics, Exevir and TargED Biopharmaceuticals and as a Board Observer of EyeD Pharma.

Diane holds a bachelor degree in informatics. She worked as administrative assistant and bookkeeper for several companies such as ADB (Siemens), VIB and Life Sciences Research Partners (still currently).